Ovarian Cancer Diagnostics Market (By Diagnosis Type: Imaging, Biopsy, Blood Test, Others; By Cancer Type: Germ Cell Tumor, Stromal Cell Tumor, Epithelial Tumor, Others; By End-Use: Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes, Others) - Global Industry Size, Share, Trends and Forecast 2019 - 2026

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
         1.1.1. Definition of Ovarian Cancer Diagnostics
         1.1.2. Market Segmentation
         1.1.3. List of Abbreviations
1.2. Summary
         1.2.1. Market Snapshot
         1.2.2. Ovarian Cancer Diagnostics Market By Diagnosis Type
         1.2.2.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison By Diagnosis Type (2015-2026)
         1.2.2.2. Global Ovarian Cancer Diagnostics Market Revenue Share By Diagnosis Type in 2017
1.2.2.3. Imaging
         1.2.2.3.1. CT Scan
         1.2.2.3.2. Ultrasound
         1.2.2.3.3. PET Scan
         1.2.2.3.4. MRI Scan
         1.2.2.3.5. Others
1.2.2.4. Biopsy
1.2.2.5. Blood Test
         1.2.2.5.1. BRCA
         1.2.2.5.2. CA125
         1.2.2.5.3. ER & PR
         1.2.2.5.4. HER2
         1.2.2.5.5. CEA
         1.2.2.5.6. KRAS Mutation
         1.2.2.5.7. Others
1.2.2.6. Others
1.2.3. Ovarian Cancer Diagnostics Market By Cancer Type
         1.2.3.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison By Cancer Type (2015-2026)
         1.2.3.2. Germ Cell Tumor
         1.2.3.3. Stromal Cell Tumor
         1.2.3.4. Epithelial Tumor
         1.2.3.5. Others
1.2.4. Ovarian Cancer Diagnostics Market By End Users
         1.2.4.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison By End Users (2015-2026)
         1.2.4.2. Cancer Diagnostic Centers
         1.2.4.3. Hospital Laboratories
         1.2.4.4. Research Institutes
         1.2.4.5. Others
1.2.5. Ovarian Cancer Diagnostics Market by Geography
         1.2.5.1. Global Ovarian Cancer Diagnostics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
         1.2.5.2. North America Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
         1.2.5.3. Europe Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
         1.2.5.4. Asia-Pacific Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
         1.2.5.5. Latin America Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)
         1.2.5.6. Middle East and Africa (MEA) Ovarian Cancer Diagnostics Market Revenue and Growth Rate(2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
         2.4.1. Bargaining Power of Suppliers
         2.4.2. Bargaining Power of Buyers
         2.4.3. Threat of Substitute
         2.4.4. Threat of New Entrants
         2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
         2.6.1. Raw Material and Suppliers
         2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
         2.8.1. Player Positioning Analysis
         2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Hospital Laboratories Production Date of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Ovarian Cancer Diagnostics Major Manufacturers in 2017

CHAPTER 4. OVARIAN CANCER DIAGNOSTICS MARKET BY DIAGNOSIS TYPE

4.1. Imaging
         4.1.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         4.1.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
         4.1.3. CT Scan
         4.1.4. Ultrasound
         4.1.5. PET Scan
         4.1.6. MRI Scan
         4.1.7. Others
4.2. Biopsy
         4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Blood Test
         4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
         4.3.3. BRCA
         4.3.4. CA125
         4.3.5. ER & PR
         4.3.6. HER2
         4.3.7. CEA
         4.3.8. KRAS Mutation
         4.3.9. Others
4.4. Other
         4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. OVARIAN CANCER DIAGNOSTICS MARKET BY CANCER TYPE

5.1. Global Ovarian Cancer Diagnostics Revenue by Cancer Type
5.2. Germ Cell Tumor
         5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Stromal Cell Tumor
         5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Epithelial Tumor
         5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
         5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. OVARIAN CANCER DIAGNOSTICS MARKET BY END USERS

6.1. Global Ovarian Cancer Diagnostics Revenue By End Users
6.2. Cancer Diagnostic Centers
         6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Hospital Laboratories
         6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Research Institutes
         6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
         6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
         6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

7.1. North America Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
         7.3.1. U.S.Ovarian Cancer Diagnostics Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         7.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         7.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.4. Canada
         7.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         7.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         7.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.5. Mexico
         7.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         7.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         7.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

8.1. Europe Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
         8.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         8.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         8.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.4. Germany
         8.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         8.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         8.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.5. France
         8.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         8.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         8.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.6. Spain
         8.6.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         8.6.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         8.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.7. Rest of Europe
         8.7.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         8.7.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         8.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

9.1. Asia-Pacific Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
         9.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         9.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         9.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.4. Japan
         9.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         9.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         9.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.5. India
         9.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         9.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         9.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.6. Australia
         9.6.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         9.6.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         9.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.7. South Korea
         9.7.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         9.7.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         9.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
         9.8.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         9.8.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         9.8.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

10.1. Latin America Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
         10.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         10.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         10.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.4. Argentina
         10.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         10.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         10.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.5. Rest of Latin America
         10.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         10.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         10.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

11.1. Middle East Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
         11.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         11.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         11.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.4. UAE
         11.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         11.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         11.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.5. Rest of Middle East
         11.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         11.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         11.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA OVARIAN CANCER DIAGNOSTICS MARKET BY COUNTRY

12.1. Africa Ovarian Cancer Diagnostics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Ovarian Cancer Diagnostics Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
         12.3.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         12.3.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         12.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.4. Egypt
         12.4.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         12.4.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         12.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.5. Rest of Africa
         12.5.1. Market Revenue and Forecast BY Diagnosis Type, 2015 - 2026 ($Million)
         12.5.2. Market Revenue and Forecast BY Cancer Type, 2015 - 2026 ($Million)
         12.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. GlaxoSmithKline plc
         13.1.1. Company Snapshot
         13.1.2. Overview
         13.1.3. Financial Overview
         13.1.4. Type Portfolio
         13.1.5. Key Developments
         13.1.6. Strategies
13.2. F. Hoffmann-La Roche Ltd.
         13.2.1. Company Snapshot
         13.2.2. Overview
         13.2.3. Financial Overview
         13.2.4. Type Portfolio
         13.2.5. Key Developments
         13.2.6. Strategies
13.3. AstraZeneca plc
         13.3.1. Company Snapshot
         13.3.2. Overview
         13.3.3. Financial Overview
         13.3.4. Type Portfolio
         13.3.5. Key Developments
         13.3.6. Strategies
13.4. Johnson & Johnson Services, Inc.
         13.4.1. Company Snapshot
         13.4.2. Overview
         13.4.3. Financial Overview
         13.4.4. Type Portfolio
         13.4.5. Key Developments
         13.4.6. Strategies
13.5. Siemens Healthcare GmbH
         13.5.1. Company Snapshot
         13.5.2. Overview
         13.5.3. Financial Overview
         13.5.4. Type Portfolio
         13.5.5. Key Developments
         13.5.6. Strategies
13.6. Bio-Rad Technologies Inc.
         13.6.1. Company Snapshot
         13.6.2. Overview
         13.6.3. Financial Overview
         13.6.4. Type Portfolio
         13.6.5. Key Developments
         13.6.6. Strategies
13.7. Thermo Fisher Scientific
         13.7.1. Company Snapshot
         13.7.2. Overview
         13.7.3. Financial Overview
         13.7.4. Type Portfolio
         13.7.5. Key Developments
         13.7.6. Strategies
13.8. Abbott
         13.8.1. Company Snapshot
         13.8.2. Overview
         13.8.3. Financial Overview
         13.8.4. Type Portfolio
         13.8.5. Key Developments
         13.8.6. Strategies
13.9. Others
         13.9.1. Company Snapshot
         13.9.2. Overview
         13.9.3. Financial Overview
         13.9.4. Type Portfolio
         13.9.5. Key Developments
         13.9.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
         14.1.1. Initial Data Search
         14.1.2. Secondary Research
         14.1.3. Primary Research
14.2. Assumptions and Scope